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aim: To identify and characterize cancer stem cells (CSC) in moderately differentiated 
buccal mucosa squamous cell carcinoma (MDBMSCC).
Methods: Four micrometer-thick, formalin-fixed, paraffin-embedded MDBMSCC sam-
ples from six patients underwent 3,3-diaminobenzidine (DAB) immunohistochemical 
(IHC) staining for the embryonic stem cell (ESC) markers, NANOG, OCT4, SALL4, SOX2, 
and pSTAT3; cancer stem cell marker, CD44; squamous cell carcinoma (SCC) marker, 
EMA; and endothelial marker, CD34. The transcriptional activities of the genes encoding 
NANOG, OCT4, SOX2, SALL4, STAT3, and CD44 were studied using NanoString gene 
expression analysis and colorimetric in  situ hybridization (CISH) for NANOG, OCT4, 
SOX2, SALL4, and STAT3.
results: Diaminobenzidine and immunofluorescent (IF) IHC staining demonstrated the 
presence of (1) an EMA+/CD44+/SOX2+/SALL4+/OCT4+/pSTAT3+/NANOG+ CSC sub-
population within the tumor nests; (2) an EMA−/CD44−/CD34−/SOX2+/OCT4+/pSTAT3+/
NANOG+ subpopulation within the stroma between the tumor nests; and (3) an EMA−/
CD44−/CD34+/SOX2+/SALL4+/OCT4+/pSTAT3+/NANOG+ subpopulation on the endo-
thelium of the microvessels within the stroma. The expression of CD44, SOX2, SALL4, 
OCT4, pSTAT3, and NANOG was confirmed by the presence of mRNA transcripts, using 
NanoString analysis and NANOG, OCT4, SOX2, SALL4, and STAT3 by CISH staining.
conclusion: This study demonstrated a novel finding of three separate CSC subpop-
ulations within MDBMSCC: (1) within the tumor nests expressing EMA, CD44, SOX2, 
SALL4, OCT4, pSTAT3, and NANOG; (2) within the stroma expressing SOX2, SALL4, 
OCT4, pSTAT3, and NANOG; and (3) on the endothelium of the microvessels within the 
stroma expressing CD34, SOX2, SALL4, OCT4, pSTAT3, and NANOG.
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inTrODUcTiOn
Oral cavity cancer is the sixth most common cancer worldwide (1), with over 90% being squamous 
cell carcinoma (SCC) (1). Oral cavity squamous cell carcinoma (OCSCC) may arise from sites of 
leukoplakia or erythroplakia involving the oral squamous epithelium (2, 3), characterized by its 
dysplastic morphology. Late-stage disease often presents with nodal metastases and less commonly, 
metastasis to the lung, brain, bone, and liver (2, 3).
2Yu et al. Cancer Stem Cells in Buccal Mucosal SCC
Frontiers in Surgery | www.frontiersin.org August 2016 | Volume 3 | Article 46
Oral cavity squamous cell carcinoma affects the oral tongue, 
floor of the mouth, buccal mucosa, hard palate, mandibular and 
maxillary alveolus, vestibule of mouth, and retromolar trigone 
(4, 5). While buccal mucosal squamous cell carcinoma (BMSCC) 
accounts for <10% of all OCSCC in the Western world (4, 6), 
it is the most prevalent OCSCC in South East Asia and South 
Asia (6, 7). This high prevalence is primarily due to the practice 
of betel nut chewing (6, 7), and/or alcohol consumption (8) 
and/or tobacco use (5), although recent studies suggest other 
non-lifestyle contributing factors (5). Due to the particularly 
aggressive nature of this cancer (9), patients with BMSCC have 
a high locoregional recurrence rate of up to 57% with associated 
poor survival (10). Despite improvements in diagnosis and treat-
ments, 5-year survival rates have remained around 50% since 
the early 1980s (4–7). Current treatment of BMSCC involves a 
multimodal approach (11), usually requiring surgical resection 
with postoperative adjuvant radiotherapy (RT) and occasionally 
chemotherapy (ChT), especially in cases with adverse features, 
such as positive surgical margins and/or extracapsular spread of 
the nodal metastases (11).
It has been proposed that the development and spread of 
many cancers (12–14), including OCSCC (15), are driven by a 
subpopulation of cancer cells known as cancer stem cells (CSC) 
(12). Recent studies have identified these CSC in OCSCC by their 
expression of the embryonic stem cell (ESC) markers, NANOG 
(15), SOX2 (16), SALL4 (17), phosphorylated (activated) form of 
signal transducer and activator of transcription 3 (pSTAT3) (18), 
and OCT4 (15, 16). NANOG is a transcription factor that controls 
cell proliferation, migration, and invasion (19). SOX2 is critical for 
the self-renewal properties of ESC (16). OCT4 is a POU domain 
transcription factor associated with cell self-renewal, prolifera-
tion, and pluripotency (16) and works synergistically with SOX2 
to regulate pluripotency of ESC (19). This pluripotency network 
also includes additional factors, such as SALL4, a transcriptional 
activator of POU5f1 that maintains embryonic pluripotency by 
modulating the expression of OCT4 (20), and pSTAT3, which 
is required for tumor formation and growth, and suppression of 
apoptosis (21). The cell surface marker CD44 is a multistructural 
and multifunctional CSC marker associated with angiogenesis, 
cell proliferation, migration, and differentiation (22), as well as 
some progenitor cell properties (23). Unlike progenitor cells and 
differentiated cells, CSCs possess the ability for self-renewal and 
multilineage differentiation through either asymmetric or sym-
metric cell division (12). It has been reported that the presence of 
CSC is associated with both a greater capacity for tumor growth 
and a worsening prognosis (13, 15). This is supported by the idea 
that CSC have unique abilities to resist cell damage and may 
represent critical mediators for both RT and ChT resistance (24).
Despite recent literature showing the presence of CSC within 
many cancers, including breast (25), brain (26), and pancreatic 
(27) cancer, there have been no reports describing the presence 
of CSC within BMSCC.
This study investigated the expression, within moderately differ-
entiated buccal mucosa squamous cell carcinoma (MDBMSCC), 
of the ESC markers NANOG, SOX2, SALL4, pSTAT3, OCT4, 
and CD44, at both the transcriptional and translational level, to 
identify and characterize the putative CSC population.
MaTerials anD MeThODs
Tissue samples
Previously untreated MDBMSCCs from five male and one female 
patients, aged 38–80 (mean, 59) years, were used in this study, 
which was approved by the Central Health and Disabilities Ethics 
Committee (ref. no. 12/CEN/74).
histochemical staining and 
immunohistochemical staining
Hematoxylin and eosin staining was performed on 4 μm-thick, 
formalin-fixed, paraffin-embedded blocks of six MDBMSCC 
samples, to confirm the appropriate histological grading and 
the presence of BMSCC in the sections. 3,3-Diaminobenzidine 
(DAB) immunohistochemical (IHC) staining of the sections was 
then performed using the Leica Bond Rx auto-stainer (Leica, 
Nussloch, Germany), as previously described (28). Staining for 
NANOG (1:2000; cat# NBP1-04320, Novus Biologicals LLC, 
Littleton, CO, USA), SOX2 (1:500; cat# PA-094, Thermo Fisher 
Scientific, Rockford, IL, USA), SALL4 (1:30; cat# CM385M-16, 
Cell Marque, Rocklin, CA, USA), pSTAT3 (1:100; cat# 9145, Cell 
Signaling Technology, Danvers, MA, USA), and OCT4 (1:200; 
cat# NBP1-47923, Novus Biologicals LLC, Littleton, CO, USA), 
CD34 (ready-to-use; cat# PA0212, Leica), CD44 (1:1500; cat# 
MRQ-13, Cell Marque), and epithelial membrane antigen (EMA, 
ready-to-use; cat# PA0212, Leica), diluted with Bond™ primary 
antibody diluent (Leica AR9352), was done for all tissue samples.
To confirm co-expression of two proteins, representative slides 
of MDBMSCC (n = 2) underwent immunofluorescent (IF) IHC 
staining using a combination of Vectafluor Excel anti-rabbit 594 
(ready-to-use; cat# VEDK-1594, Vector Laboratories, Burlingame, 
CA, USA) and Alexa Fluor anti-mouse 488 (1:500; cat# A21202, 
Life Technologies) so as to detect combinations that included 
NANOG, SOX2, and pSTAT3, and Vectafluor Excel anti-mouse 
(ready-to-use; cat# VEDK2488, Vector Laboratories) and Alexa 
Fluor anti-rabbit 594 (1:500; cat# A21207, Life Technologies) to 
detect combinations that included CD44, EMA, OCT4, or SALL4.
Positive control tissues used for the primary antibodies were 
human infantile hemangioma (IH) for NANOG (29), and SALL4 
(30), myometrium for OCT4 (31), skin for SOX2 (32), tonsil for 
pSTAT3 (33) and CD44 (34). A negative control for the primary 
antibody was performed on a MDBMSCC sample from the 
cohort of patients used for IHC staining.
nanostring gene expression analysis
RNA was extracted from five snap-frozen MDBMSCC samples 
from the same cohort of patients used for DAB IHC staining and 
was used for NanoString nCounter™ Gene Expression Assay 
(Nanostring Technologies, Seattle, WA, USA). Total RNA was 
extracted using the MagJET RNA kit (Thermo Fisher Scientific) 
with the protocol adapted for tissue and run on a KingFisher 
Duo machine (Thermo Fisher Scientific). RNA samples were 
then quantitated on a Qubit® 2.0 fluorometer (Invitrogen, Life 
Technologies) and were subject to RNA integrity analysis via 
the 2100 Bioanalyzer Instrument (Agilent Technologies). The 
samples then underwent NanoString nCounter gene expres-
sion assay performed by New Zealand Genomics (Dunedin, 
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New Zealand) according to the manufacturer’s protocol. Probes 
for the genes encoding NANOG (NM_024865.2), SALL4 
(NM_020436.3) SOX2 (NM_003106.2), OCT4 (NM_002701.4), 
CD44 (NM_001001392.1), and STAT3 (NM_139276.2) and the 
housekeeping gene GUSB (NM_000181.1) were designed and 
manufactured by NanoString Technologies. Raw data were ana-
lyzed using nSolver™ software (NanoString Technologies) using 
standard settings and normalized against the housekeeping gene.
colorimetric In Situ hybridization
Representative 4  μm-thick, formalin-fixed, paraffin-embedded 
sections of three MDBMSCC samples from the original cohort 
of six patients used for DAB IHC staining were used for mRNA 
colorimetric in situ hybridization (CISH). Staining was done on 
the Leica Bond Rx auto-stainer and detected using the ViewRNA 
red stain kit (Affymetrix, Santa Clara, CA, USA), as previously 
described (35). The probes used for NANOG (NM_024865), SOX2 
(NM_003106), SALL4 (NM_020436), STAT3 (NM_003150), and 
OCT4 (NM_002701) were obtained from Affymetrix. Positive 
controls used were human IH for SALL4 and human seminoma 
for NANOG, SOX2, OCT4, and STAT3. A negative control for the 
primary antibody was done on a sample of MDBMSCC from the 
CISH cohort by omitting the probe.
image analysis
Diaminobenzidine IHC- and CISH-stained slides were viewed 
and imaged using an Olympus BX53 light microscope (Tokyo, 
Japan). IF IHC-stained images were captured using an Olympus 
FV1200 biological confocal laser-scanning microscope and 
processed with the cellSens Dimension 1.11 software using 2D 
deconvolution algorithm (Olympus).
resUlTs
histochemical and immunohistochemical 
staining
Hematoxylin and eosin staining confirmed the appropriate histo-
logical grading and the presence of MDBMSCC on the slides used 
for DAB IHC staining (data not shown).
Diaminobenzidine IHC staining showed that cells within 
the tumor nests stained positively with the SCC marker EMA 
(Figure 1A, brown). Both SOX2 (Figure 1B, brown) and SALL4 
(Figure  1C, brown) showed positive nuclear staining with 
increased expression especially toward the periphery of the 
tumor nests. Nuclear staining for OCT4 (Figure  1D, brown) 
and pSTAT3 (Figure  1E, brown) of the cells within the tumor 
nests was noted, while primarily cytoplasmic staining with some 
nuclear positivity for NANOG (Figure 1F, brown) was observed. 
There was also membranous expression of the CSC marker CD44 
(Figure 1G, brown) that was exclusively localized to cells within 
the tumor nests. Clusters of cells within the stroma also showed 
nuclear expression of SOX2 (Figure  1B, brown, arrowheads), 
OCT4 (Figure 1D, brown, arrowheads), and pSTAT3 (Figure 1E, 
brown, arrowheads), while cytoplasmic and nuclear expression of 
NANOG (Figure 1F, brown, arrowheads) was observed in these 
cells. The endothelium of the microvessels within the stroma also 
stained positively for SOX2 (Figure  1B, brown, thin arrows), 
SALL4 (Figure  1C, brown, thin arrows), OCT4 (Figure  1D, 
brown, thin arrows), pSTAT3 (Figure  1E, brown, thin arrows), 
and NANOG (Figure 1F, brown, thin arrows).
Expected staining patterns for the NANOG (Figure  S1A 
in Supplementary Material, brown), SALL4 (Figure  S1B 
in Supplementary Material, brown), OCT4 (Figure  S1C 
in Supplementary Material, brown), SOX2 (Figure  S1D in 
Supplementary Material, brown), pSTAT3 (Figure  S1E in 
Supplementary Material, brown), and CD44 (Figure  S1F in 
Supplementary Material, brown) were demonstrated in the 
respective positive controls. The omission of the primary anti-
body in MDBMSCC samples provided an appropriate negative 
control (Figure S1G in Supplementary Material).
To demonstrate co-expression of the ESC markers, IF IHC 
staining was performed on two representative MDBMSCC sam-
ples used for DAB IHC staining. pSTAT3 staining (Figures 2A,B, 
red) was localized to cells within the tumor nests that displayed 
membranous staining for EMA (Figure  2A, green), the 
endothelium of the microvessels that stained positively for CD34 
(Figure  2B, green) and cells within the stroma. NANOG was 
expressed by cells within the tumor nests (Figure 2C, red) and 
the stroma (Figure 2C, red), as well as the endothelium of the 
microvessels that stained positively for CD34 (Figure 2C, green). 
A similar staining pattern was also seen with SOX2 for cells within 
the tumor nests (Figure  2D, red) and the stroma (Figure  2D, 
red), and the endothelium marked by CD34 (Figure 2D, green). 
SOX2 (Figure  2E, red) and SALL4 (Figure  2E, green) were 
co-expressed (appearing as orange) by cells within the tumor 
nests and the stroma (Figure  2E), and the endothelium of the 
microvessels (Figure 2E, red). SOX2 (Figure 2F, red) and OCT4 
(Figure 2F, green) were also co-localized (appearing as orange) 
to cells within the tumor nests and the stroma (Figure  2F), 
and the endothelium of the microvessels (Figure 2F). pSTAT3 
(Figure 2G, red) and membranous staining of CD44 (Figure 2G, 
green) were co-expressed by cells within the tumor nests. 
Images of the individual stains are presented in Figure  S2 in 
Supplementary Material.
nanostring gene analysis
NanoString analysis confirmed the presence of the mRNA tran-
scripts for NANOG, OCT4, SALL4, SOX2, STAT3, and CD44, 
in MDBMSCC samples of all five patients, while SALL4 was 
detected in four of the five samples (Figure 3).
colorimetric In Situ hybridization
Colorimetric in  situ hybridization confirmed the pres-
ence of  mRNA for SOX2 (Figure  4A, pink, arrows), SALL4 
(Figure  4B, pink, arrows), OCT4 (Figure  4C, pink, arrows), 
STAT3 (Figure  4D, pink, arrows), and NANOG (Figure  4E, 
pink, arrows) in the cells within all three MDBMSCC 
samples.
DiscUssiOn
The recent literature supporting the concept of CSC in carcino-
genesis has reported on the presence of these cells in multiple 
cancer types (12–14). The findings of this study further support 
FigUre 1 | representative DaB ihc-stained sections of MDBMscc demonstrating nuclear expression of eMa of cells within the tumor nests [(a), 
brown]. Expression of SOX2 was seen in cells within the tumor nests [(B), brown, thick arrows] and the stroma [(B), brown, arrowheads], and on the endothelium of 
the microvessels within the stroma [(B), brown, thin arrows]. Expression of SALL4 was limited to cells within the tumor nests [(c), brown, thick arrows] and the 
endothelium of the microvessels [(c), brown, thin arrows]. OCT4 was also expressed in cells within tumor nests [(D), brown, thick arrows] and the stroma [(D), 
brown, arrowheads], and the endothelium of the microvessels within the stroma [(D), brown, thin arrows]. Expression of pSTAT3 was detected on cells within the 
tumor nests [(e), brown, thick arrows] and the stroma [(e), brown, arrowheads], and the endothelium of the microvessels within the stroma [(e), brown, thin arrows]. 
NANOG was also seen in cells within the tumor nests [(F), brown, thick arrows] and the stroma [(F), brown, arrowheads], and the endothelium of the microvessels 
within the stroma [(F), brown, thin arrows]. CD44 expression was seen as membranous staining of the tumor nest cells [(g), brown]. Original magnification: 400×.
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previous reports on the presence of CSC in OCSCC (15, 36). 
The discovery of more than one subpopulation of putative 
CSC within MDBMSCC expressing ESC markers is novel. The 
detection of a EMA+/CD44+/SOX2+/OCT4+/SALL4+/pSTAT3+/
NANOG+ subpopulation within the tumor nests aligns with 
recent literature reporting localization of CSC in OCSCC (15, 36), 
particularly at the “tumor front” (37). To the best of our knowledge, 
this is the first report demonstrating a EMA−/CD34+/CD44−/
FigUre 2 | representative iF ihc-stained sections of MDBMscc demonstrating the expression of psTaT3 [(a), red] and eMa [(a), green] by cells 
within the tumor nests.  
 (Continued)
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FigUre 3 | expression of csc-related mrna transcripts of nanOg, OcT4, sall4, sOX2 sTaT3, and cD44 in MDBMscc samples from five patients. 
Their expression was normalized over GUSB housekeeper.
There was a CSC subpopulation remonstrating nuclear co-expression of STAT3 [(B), red] and CD34 [(B), green], appearing as orange, on the endothelium of the 
microvessels within the stroma; and another subpopulation staining only positively for pSTAT3 within the stroma [(B), red]. Nuclear expression of NANOG [(c), red] 
was demonstrated on the endothelium of the microvessels which expressed CD34 [(c), green] within stroma. The NANOG+ cells [(c), red] that do not express 
CD34 were seen within the tumor nests and the stroma. SOX2 [(D), red] was also expressed by cells within tumor nests and the stroma, and the endothelium of the 
microvessels expressing CD34 [(D), green]. Nuclear expression of both SOX2 [(e), red] and SALL4 [(e), green], appearing as orange, was seen on the cells within 
the tumor nests and the stroma. Expression of both SOX2 [(F), red] and OCT4 [(F), green], appearing as orange, was seen on cells within the tumor nests and the 
stroma, and the endothelium of the microvessels within the stroma. pSTAT3 [(g), red] and membranous staining CD44 [(g), green] were co-expressed by cells 
within the tumor nests. Scale bars: 20 μm.
FigUre 2 | continued
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SOX2+/OCT4+/SALL4+/pSTAT3+/NANOG+ subpopulation on 
the endothelium of the microvessels, and a separate EMA−/
CD44−/CD34−/SOX2+/OCT4+/SALL4+/pSTAT3+/NANOG+ 
subpopulation within the stroma of MDBMSCC. It is exciting to 
speculate that the abundant expression of these ESC markers, and 
therefore CSC, which are known to be associated with cell prolif-
eration, invasion, and inhibition of cell death (19), is a reflection 
of the particularly aggressive nature of this cancer.
Interestingly, the ESC markers SOX2, OCT4, SALL4, pSTAT3, 
and NANOG, showed both nuclear and cytoplasmic expression. 
This novel finding in MDBMSCC is consistent with previous 
studies reporting on cytoplasmic expression of NANOG in cervi-
cal cancer (38) and SALL4 in breast cancer (39) cells, inferring 
cytoplasmic expression as a predictor of poor prognosis (39). The 
reasons for this are the topic of further investigation.
This novel demonstration of the co-expression of ESC markers 
within the endothelium of the microvessels and the cells within 
the stroma may be a result of an epithelial-to-mesenchymal tran-
sition (EMT) and vascular mimicry, which have been previously 
demonstrated within breast (40) and head and neck (41) cancers. 
It is exciting to speculate that the CSC in MDBMSCC undergo 
EMT and preferentially express OCT4, pSTAT3, SOX2, and 
NANOG and potentially lose the expression of EMA and CD44, 
as none of these cells outside of the tumor nests express EMA 
or CD44. A reason for this is the potential loss of the relatively 
more downstream markers EMA and CD44, as the cells adopt a 
more stem-like phenotype with the ability to undergo EMT (42). 
This would be consistent with a previous report demonstrating 
the increased expression of the EMT-associated genes, twist 
and snail1, in the stromal population of pharyngeal SCC (43). 
Alternatively, these three CSC subpopulations may be distinct 
from one another, each playing a vital role in carcinogenesis. 
However, this is beyond the scope of this study.
The expression of ESC markers by the endothelium of 
the microvessels demonstrated by IHC and CISH staining is 
fascinating and merits further investigation. Curiously, while 
all five ESC markers were demonstrated using IHC staining, 
NanoString analysis confirmed the presence of the mRNA 
transcripts CD44, NANOG, OCT4, SOX2, and STAT3 in all 
the MDBMSCC samples from all five patients, while SALL4 
was detected in only four of the five samples. A possible rea-
son for this is the heterogeneous nature of cancer tissues. The 
abundance of cells within MDBMSCC expressing stem cell 
markers demonstrated by us is consistent with similar reports 
on hypopharyngeal SCC (44). Our findings of OCT4 expression 
in the tumor nests is similar to that reported by Ge et al. (44) 
showing OCT4 staining within hypopharyngeal SCC. However, 
we have also demonstrated the presence of an independent 
OCT4+ subpopulation within the stroma, consistent with the 
findings of Huang et al. (16).
FigUre 4 | representative cish-stained sections of MDBMscc demonstrating mrna expression of sOX2 [(a), pink, arrows], sall4 [(B), pink, 
arrows], OcT4 [(c), pink, arrows], sTaT3 [(D), pink, arrows], and nanOg [(e), pink, arrows]. Original magnification: 1000×.
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Our demonstration of the presence of three putative CSC 
subpopulations within MDBMSCC adds further insight into 
the biology of this disease, highlighting a potential vital role 
for CSC in tumor growth and development, locoregional and 
distant metastatic spread, and resistance to RT and ChT. A greater 
understanding of the CSC, by characterizing the subpopulations 
in well and poorly differentiated BMSCC lesions using these same 
markers, as well as further investigations into their microenviron-
ment and their regulatory pathways, may reveal novel therapeutic 
targets for this aggressive cancer.
TaKe hOMe Messages
(1) This study demonstrates the novel finding of three CSC sub-
populations within MDBMSCC, with; (2) one CSC subpopulation 
within the tumor nests, expressing EMA, CD44, SOX2, SALL4, 
OCT4, pSTAT3, and NANOG; (3) a second CSC subpopulation 
is within the stroma between the tumor nests, expressing SOX2, 
SALL4, OCT4, pSTAT3, and NANOG; and (4) a third CSC 
subpopulation expressing CD34, SOX2, SALL4, OCT4, pSTAT3, 
and NANOG localized to the endothelium of the microvessels 
within the stroma.
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Figure s1 | DaB ihc-stained sections of human infantile hemangioma 
for nanOg [(a), brown] and sall4 [(B), brown], myometrium for OcT4 
[(c), brown], skin for sOX2 [(D), brown], tonsil for psTaT3 [(e), brown] 
and cD44 [(F), brown], and the omission of the primary antibody in a 
moderately differentiated MDBMscc sample provided an appropriate 
negative control [(g), brown]. Cellular nuclei were counterstained with 
hematoxylin [(a–F), blue]. Original magnification: 400×.
Figure s2 | representative iF ihc-stained sections of MDBMscc 
demonstrating nuclear expression of psTaT3 [(a,c,M), red], eMa [(B), 
green], nanOg [(e), red], cD34 [(D,F,h), green], sOX2 [(g,i,K), red], 
sall4 [(J), green], OcT4 [(l), green], and cD44 [(n), green]. Separated 
images of the individual stains shown in (a–n). Scale bars: 20 μm.
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